Randomized controlled trials of new oral anticoagulants for stroke prevention in atrial fibrillation

Roger, 2012, Heart disease and stroke statistics - 2012 update: a report from the American Heart Association., Circulation, 125, e2

Naccarelli, 2009, Increasing prevalence of atrial fibrillation and flutter in the United States., Am J Cardiol, 104, 1534, 10.1016/j.amjcard.2009.07.022

Hart, 2007, Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation., Ann Intern Med, 146, 857, 10.7326/0003-4819-146-12-200706190-00007

Lip, 2011, Bleeding risk assessment and management in atrial fibrillation patients. Executive Summary of a Position Document from the European Heart Rhythm Association EHRA, endorsed by the European Society of Cardiology ESC Working Group on Thrombosis., Thromb Haemost, 106, 997, 10.1160/TH11-10-0690

Budnitz, 2011, Emergency hospitalizations for adverse drug events in older Americans., N Engl J Med, 365, 2002, 10.1056/NEJMsa1103053

Connolly, 2009, Effect of clopidogrel added to aspirin in patients with atrial fibrillation., N Engl J Med, 360, 2066, 10.1056/NEJMoa0901301

Connolly, 2006, Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial., Lancet, 367, 1903, 10.1016/S0140-6736(06)68845-4

Cairns, 2011, Canadian Cardiovascular Society atrial fibrillation guidelines 2010: prevention of stroke and systemic thromboembolism in atrial fibrillation and flutter., Can J Cardiol, 27, 74, 10.1016/j.cjca.2010.11.007

Camm, 2010, Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC)., Eur Heart J, 31, 2369, 10.1093/eurheartj/ehq278

Wann, 2011, 2011 ACCFAHAHRS focused update on the management of patients with atrial fibrillation (update on dabigatran): a report of the American College of Cardiology FoundationAmerican Heart Association Task Force on practice guidelines., J Am Coll Cardiol, 57, 1330, 10.1016/j.jacc.2011.01.010

Fuster, 2011, 2011 ACCFAHAHRS focused updates incorporated into the ACCAHAESC 2006 Guidelines for the management of patients with atrial fibrillation: a report of the American College of Cardiology FoundationAmerican Heart Association Task Force on Practice Guidelines developed in partnership with the European Society of Cardiology and in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society., J Am Coll Cardiol, 57, e101, 10.1016/j.jacc.2010.09.013

Go, 1999, Warfarin use among ambulatory patients with nonvalvular atrial fibrillation: the anticoagulation and risk factors in atrial fibrillation (ATRIA) study., Ann Intern Med, 131, 927, 10.7326/0003-4819-131-12-199912210-00004

Deplanque, 2004, Stroke prevention and atrial fibrillation: reasons leading to an inappropriate management. Main results of the SAFE II study., Br J Clin Pharmacol, 57, 798, 10.1111/j.1365-2125.2004.02086.x

Lin, 2008, Compliance with antithrombotic prescribing guidelines for patients with atrial fibrillation - a nationwide descriptive study in Taiwan., Clin Ther, 30, 1726, 10.1016/j.clinthera.2008.09.010

Connolly, 2008, Benefit of oral anticoagulant over antiplatelet therapy in atrial fibrillation depends on the quality of international normalized ratio control achieved by centers and countries as measured by time in therapeutic range., Circulation, 118, 2029, 10.1161/CIRCULATIONAHA.107.750000

Gallagher, 2011, Risks of stroke and mortality associated with suboptimal anticoagulation in atrial fibrillation patients., Thromb Haemost, 106, 968, 10.1160/TH11-05-0353

Rose, 2011, Risk-adjusted percentage time in therapeutic range as a quality indicator for outpatient oral anticoagulation: results of the Veterans Affairs Study to Improve Anticoagulation (VARIA)., Circ Cardiovasc Qual Outcomes, 4, 22, 10.1161/CIRCOUTCOMES.110.957738

Baker, 2009, Meta-analysis to assess the quality of warfarin control in atrial fibrillation patients in the United States., J Manag Care Pharm, 15, 244, 10.18553/jmcp.2009.15.3.244

Ford, 2007, Direct thrombin inhibition and stroke prevention in elderly patients with atrial fibrillation: experience from the SPORTIF III and V Trials., Stroke, 38, 2965, 10.1161/STROKEAHA.107.488007

Pisters, 2010, A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey., Chest, 138, 1093, 10.1378/chest.10-0134

Connolly, 2009, Dabigatran versus warfarin in patients with atrial fibrillation., N Engl J Med, 361, 1139, 10.1056/NEJMoa0905561

Connolly, 2010, Newly identified events in the RE-LY trial., N Engl J Med, 363, 1875, 10.1056/NEJMc1007378

Hohnloser, 2012, Myocardial ischemic events in patients with atrial fibrillation treated with dabigatran or warfarin in the RE-LY Trial., Circulation, 125, 669, 10.1161/CIRCULATIONAHA.111.055970

Lip, 2010, Does warfarin for stroke thromboprophylaxis protect against MI in atrial fibrillation patients Am J M, ed, 123, 785

Uchino, 2012, Dabigatran association with higher risk of acute coronary events: meta-analysis of noninferiority randomized controlled trials., Arch Intern Med, 172, 397, 10.1001/archinternmed.2011.1666

Ezekowitz, 2010, Dabigatran and warfarin in vitamin K antagonist-naive and -experienced cohorts with atrial fibrillation., Circulation, 122, 2246, 10.1161/CIRCULATIONAHA.110.973735

Diener, 2010, Dabigatran compared with warfarin in patients with atrial fibrillation and previous transient ischaemic attack or stroke: a subgroup analysis of the RE-LY trial., Lancet Neurol, 9, 1157, 10.1016/S1474-4422(10)70274-X

Hori, 2011, Efficacy and safety of dabigatran vs. warfarin in patients with atrial fibrillation - sub-analysis in Japanese population in RE-LY trial., Circ J, 75, 800, 10.1253/circj.CJ-11-0191

Nagarakanti, 2011, Dabigatran versus warfarin in patients with atrial fibrillation: an analysis of patients undergoing cardioversion., Circulation, 123, 131, 10.1161/CIRCULATIONAHA.110.977546

Wallentin, 2010, Efficacy and safety of dabigatran compared with warfarin at different levels of international normalised ratio control for stroke prevention in atrial fibrillation: an analysis of the RE-LY trial., Lancet, 376, 975, 10.1016/S0140-6736(10)61194-4

Eikelboom, 2012, Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: an analysis of the randomized evaluation of long-term anticoagulant therapy (RE-LY) trial., Circulation, 123, 2363, 10.1161/CIRCULATIONAHA.110.004747

Connolly, 2011, Apixaban in patients with atrial fibrillation., N Engl J Med, 364, 806, 10.1056/NEJMoa1007432

Eikelboom, 2010, Rationale and design of AVERROES: apixaban versus acetylsalicylic acid to prevent stroke in atrial fibrillation patients who have failed or are unsuitable for vitamin K antagonist treatment., Am Heart J, 159, 348, 10.1016/j.ahj.2009.08.026

Lopes, 2010, Apixaban for reduction in stroke and other ThromboemboLic events in atrial fibrillation (ARISTOTLE) trial: design and rationale., Am Heart J, 159, 331, 10.1016/j.ahj.2009.07.035

Granger, 2011, Apixaban versus warfarin in patients with atrial fibrillation., N Engl J Med, 365, 981, 10.1056/NEJMoa1107039

Patel, 2011, Rivaroxaban versus warfarin in nonvalvular atrial fibrillation., N Engl J Med, 365, 883, 10.1056/NEJMoa1009638

Fox, 2011, Prevention of stroke and systemic embolism with rivaroxaban compared with warfarin in patients with nonvalvular atrial fibrillation and moderate renal impairment., Eur Heart J, 32, 2387, 10.1093/eurheartj/ehr342

Ruff, 2010, Evaluation of the novel factor Xa inhibitor edoxaban compared with warfarin in patients with atrial fibrillation: design and rationale for the Effective aNticoaGulation with factor xA next GEneration in Atrial Fibrillation-Thrombolysis In Myocardial Infarction study 48 (ENGAGE AF-TIMI 48)., Am Heart J, 160, 635, 10.1016/j.ahj.2010.06.042